We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.
- Authors
Ding Chen; Gallagher, Sandra; Monson, Nancy L.; Herbst, Ronald; Yue Wang
- Abstract
Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B cell targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19 positive plasmablasts and plasma cells. Inebilizumab (MEDI 551), an anti CD19 antibody with enhanced antibody dependent cell mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients.
- Subjects
B cells; IMMUNOGLOBULIN analysis; PLASMA cells; DRUG efficacy; AUTOIMMUNE diseases; PATIENTS
- Publication
Journal of Clinical Medicine, 2016, Vol 5, Issue 12, p107
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm5120107